BBGI PCL (SET: BBGI) Debuts Shares on the SET March 17

Aiming to be a leading bio-product group with green innovation and sustainability BBGI PCL (SET: BBGI), a leader in the biofuel energy industry and...
SinoMab

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Approved by FDA

SinoMab BioScience Limited (SinoMab or the Company, together with its subsidiaries, the Group, HKG: 3681), a Hong Kong-based biopharmaceutical company dedicated to the research,...

Jacobson Pharma’s Chairman Uplifts Shareholding to Above 60%

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma Corporation Limited (the Company; together with its subsidiaries, the Group; HKG: 2633), a...

Resintech Bhd Acquires 30% stake in Bionutricia for RM8.7 Million

Company sees growth from use of plant and fruit extracts for food supplement and healthcare products Resintech Berhad (Bursa: RESINTC, 7232), a fully integrated provider...

Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio...

Nuance Pharma to develop and commercialize Bentrio(TM) nasal spray in Chinese Mainland, Hong Kong, Macau and South Korea Altamira to receive up to...

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure...

First-in-class peptidomimetic with distinct MoA activating trophic signaling pathways to protect and prevent damage to the optic nerve and retina Potential to be...
Avance Clinical

Avance Clinical Announces New Office Opening in Sydney

Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical...

Senior Management Further Increases Shareholdings in EC Healthcare With Strong Confidence in the Group’s...

EC Healthcare (the Company, which together with its subsidiaries is referred to as the Group, HKG: 2138), the largest non-hospital medical group in Hong...

Q&M Dental records historic highest-ever revenue and profit after tax for year ended 31...

Q&M Dental Group (Singapore) Limited ("Q&M" or together with its subsidiaries, the "Group"), a leading private dental healthcare group in Asia, today reported the...

UMP Healthcare Offers Free Telemedicine Service to COVID-19 Patients

UMP Healthcare Holdings Limited (UMP or the Group; HKG: 722) has announced that its affiliate, UMP Charity Foundation Limited (the Charity Foundation), will donate...

Lepu Biopharma Co., Ltd. Successfully Listed on the Main Board of HKEX

First Day Closed at HK$7.14, HK$0.01 Higher Than the Offer Price Representing an Increase of Approximately 0.14% The biopharmaceutical company focusing on oncology therapeutics...

MBMV invests in international bio-tech startup Arcensus GmbH

Based on Whole Genome Sequencing (WGS), Arcensus GmbH makes it possible to detect rare as well as frequent disorders such as cancer or heart...

Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full...

Alset Capital Acquisition Corp. (the "Company") announced today the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering")....

V-01 as a Sequential Booster Can Produce Good Protection against Omicron —- Latest Phase...

Global pandemic control is still facing enormous challenges after more than two years since the outbreak of the COVID-19. Following the Delta and Beta...

Bintai Kinden Corporation Berhad Emerges as Substantial Shareholder in Malaysian Genomics Resource Centre Berhad

Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, is pleased to announce the entry of a new...

Therapeutic Goods Administration of Australia Authorizes Moderna’s Covid-19 Vaccine in Children (6-11 Years)

Moderna, Inc., (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Therapeutic Goods Administration (TGA) in Australia has...
SinoMab

IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA

SinoMab BioScience Limited (SinoMab or the Company, together with its subsidiaries, the Group, HKG: 3681), a Hong Kong-based biopharmaceutical company dedicated to the research,...

Malaysian Genomics Resource Centre Berhad Records Significant Increase in Revenue of RM7.63 Million

Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, today announced that it recorded revenue of RM7.63 million...

Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries

Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise New subsidiaries to be established in Malaysia, Taiwan, Singapore, and...

Lepu Biopharma Announces Proposed Listing on the Main Board of the Hong Kong Stock...

Offer Price Between HK$6.87and HK$7.38 per H Share To Raise Proceeds Up to HK$936.3 Million Established an integrated end-to-end platform across drug discovery, clinical development and...